179 related articles for article (PubMed ID: 20596793)
1. Adrenomedullin 2/intermedin in the hypothalamo-pituitary-adrenal axis.
Takahashi K; Morimoto R; Hirose T; Satoh F; Totsune K
J Mol Neurosci; 2011 Feb; 43(2):182-92. PubMed ID: 20596793
[TBL] [Abstract][Full Text] [Related]
2. Structure-function analyses reveal a triple β-turn receptor-bound conformation of adrenomedullin 2/intermedin and enable peptide antagonist design.
Roehrkasse AM; Booe JM; Lee SM; Warner ML; Pioszak AA
J Biol Chem; 2018 Oct; 293(41):15840-15854. PubMed ID: 30139742
[TBL] [Abstract][Full Text] [Related]
3. Expression of adrenomedullin 2/intermedin in human adrenal tumors and attached non-neoplastic adrenal tissues.
Morimoto R; Satoh F; Murakami O; Hirose T; Totsune K; Imai Y; Arai Y; Suzuki T; Sasano H; Ito S; Takahashi K
J Endocrinol; 2008 Jul; 198(1):175-83. PubMed ID: 18460550
[TBL] [Abstract][Full Text] [Related]
4. Adrenomedullin 2/intermedin is a slow off-rate, long-acting endogenous agonist of the adrenomedullin
Babin KM; Karim JA; Gordon PH; Lennon J; Dickson A; Pioszak AA
J Biol Chem; 2023 Jun; 299(6):104785. PubMed ID: 37146967
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemical localization of adrenomedullin 2/intermedin-like immunoreactivity in human hypothalamus, heart and kidney.
Takahashi K; Kikuchi K; Maruyama Y; Urabe T; Nakajima K; Sasano H; Imai Y; Murakami O; Totsune K
Peptides; 2006 Jun; 27(6):1383-9. PubMed ID: 16359754
[TBL] [Abstract][Full Text] [Related]
6. Intermedin in paraventricular nucleus attenuates sympathetic activity and blood pressure via nitric oxide in hypertensive rats.
Zhou YB; Sun HJ; Chen D; Liu TY; Han Y; Wang JJ; Tang CS; Kang YM; Zhu GQ
Hypertension; 2014 Feb; 63(2):330-7. PubMed ID: 24218431
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of intermedin on cardiovascular, pulmonary and renal diseases: comparison with adrenomedullin and CGRP.
Holmes D; Campbell M; Harbinson M; Bell D
Curr Protein Pept Sci; 2013 Jun; 14(4):294-329. PubMed ID: 23745696
[TBL] [Abstract][Full Text] [Related]
8. Receptor activity-modifying protein-dependent effects of mutations in the calcitonin receptor-like receptor: implications for adrenomedullin and calcitonin gene-related peptide pharmacology.
Watkins HA; Walker CS; Ly KN; Bailey RJ; Barwell J; Poyner DR; Hay DL
Br J Pharmacol; 2014 Feb; 171(3):772-88. PubMed ID: 24199627
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of intermedin/adrenomedullin-2 in a cellular model of human pulmonary arterial hypertension.
Holmes D; Corr M; Thomas G; Harbinson M; Campbell M; Spiers P; Bell D
Peptides; 2020 Apr; 126():170267. PubMed ID: 32017948
[TBL] [Abstract][Full Text] [Related]
10. Adrenomedullin 2 (AM2)/intermedin is a more potent activator of hypothalamic oxytocin-secreting neurons than AM possibly through an unidentified receptor in rats.
Hashimoto H; Hyodo S; Kawasaki M; Shibata M; Saito T; Suzuki H; Otsubo H; Yokoyama T; Fujihara H; Higuchi T; Takei Y; Ueta Y
Peptides; 2007 May; 28(5):1104-12. PubMed ID: 17386959
[TBL] [Abstract][Full Text] [Related]
11. Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes.
Roh J; Chang CL; Bhalla A; Klein C; Hsu SY
J Biol Chem; 2004 Feb; 279(8):7264-74. PubMed ID: 14615490
[TBL] [Abstract][Full Text] [Related]
12. Expression of adrenomedullin 2/intermedin, a possible reno-protective peptide, is decreased in the kidneys of rats with hypertension or renal failure.
Hirose T; Totsune K; Mori N; Mori T; Morimoto R; Metoki H; Asayama K; Kikuya M; Ohkubo T; Kohzuki M; Takahashi K; Imai Y
Am J Physiol Renal Physiol; 2010 Jul; 299(1):F128-34. PubMed ID: 20462970
[TBL] [Abstract][Full Text] [Related]
13. Changes in the expression of calcitonin receptor-like receptor, receptor activity-modifying protein (RAMP) 1, RAMP2, and RAMP3 in rat uterus during pregnancy, labor, and by steroid hormone treatments.
Thota C; Gangula PR; Dong YL; Yallampalli C
Biol Reprod; 2003 Oct; 69(4):1432-7. PubMed ID: 12801991
[TBL] [Abstract][Full Text] [Related]
14. The pharmacology of adrenomedullin 2/intermedin.
Hong Y; Hay DL; Quirion R; Poyner DR
Br J Pharmacol; 2012 May; 166(1):110-20. PubMed ID: 21658025
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of components of the cardiomyocyte adrenomedullin/intermedin receptor system following blood pressure reduction in nitric oxide-deficient hypertension.
Zhao Y; Bell D; Smith LR; Zhao L; Devine AB; McHenry EM; Nicholls DP; McDermott BJ
J Pharmacol Exp Ther; 2006 Mar; 316(3):1269-81. PubMed ID: 16326922
[TBL] [Abstract][Full Text] [Related]
16. Selective CGRP and adrenomedullin peptide binding by tethered RAMP-calcitonin receptor-like receptor extracellular domain fusion proteins.
Moad HE; Pioszak AA
Protein Sci; 2013 Dec; 22(12):1775-85. PubMed ID: 24115156
[TBL] [Abstract][Full Text] [Related]
17. Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat.
Oliver KR; Kane SA; Salvatore CA; Mallee JJ; Kinsey AM; Koblan KS; Keyvan-Fouladi N; Heavens RP; Wainwright A; Jacobson M; Dickerson IM; Hill RG
Eur J Neurosci; 2001 Aug; 14(4):618-28. PubMed ID: 11556887
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the expression of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines.
Choksi T; Hay DL; Legon S; Poyner DR; Hagner S; Bloom SR; Smith DM
Br J Pharmacol; 2002 Jul; 136(5):784-92. PubMed ID: 12086988
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterisation of the mechanisms underlying the relaxant effect of adrenomedullin in the rat carotid artery.
Passaglia P; Gonzaga NA; Tirapelli DP; Tirapelli LF; Tirapelli CR
J Pharm Pharmacol; 2014 Dec; 66(12):1734-46. PubMed ID: 25117796
[TBL] [Abstract][Full Text] [Related]
20. Changes of adrenomedullin and its receptor components mRNAs expression in the brain stem and hypothalamus-pituitary-adrenal axis of stress-induced hypertensive rats.
Li X; Li L; Shen LL; Qian Y; Cao YX; Zhu DN
Sheng Li Xue Bao; 2004 Dec; 56(6):723-9. PubMed ID: 15614422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
